Viral suppression and viral breakthrough impact the humoral immune response to HIV infection. We evaluated the impact of viral suppression and viral breakthrough on results obtained with two cross-sectional HIV incidence assays.All samples were collected from adults in the US who were HIV infected for >2 years. Samples were tested with the BED capture enzyme immunoassay (BED-CEIA) which measures the proportion of IgG that is HIV-specific, and with an antibody avidity assay based on the Genetic Systems 1/2+ O ELISA. We tested 281 samples: (1) 30 samples from 18 patients with natural control of HIV-1 infection known as elite controllers or suppressors (2) 72 samples from 18 adults on antiretroviral therapy (ART), with 1 sample before and 2–6 ...
Aim. To estimate the antibodies (Ab) level to HIV-1 antigens in persons infected with virus various ...
Objectives: To evaluate the evolution of antibody avidity and Western blot reactivity in recently i...
BackgroundIn the placebo-controlled trial ACTG A5197, a trend favoring viral suppression was seen in...
Viral suppression and viral breakthrough impact the humoral immune response to HIV infection. We eva...
Viral suppression and viral breakthrough impact the humoral immune response to HIV infection. We eva...
Background: A major challenge to HIV eradication strategies is the lack of an accurate measurement o...
BACKGROUND: A major challenge to HIV eradication strategies is the lack of an accurate measurement o...
Although antiretroviral therapy (ART) suppresses HIV replication, ART-treated individuals must maint...
SummaryObjectivesTo evaluate the evolution of antibody avidity and Western blot reactivity in recent...
Objective: Persistence of the viral reservoir is the main barrier to curing HIV. Initiation of ART d...
BackgroundA major challenge to HIV eradication strategies is the lack of an accurate measurement of ...
Summary Objectives To evaluate the evolution of antibody avidity and Western blot reactivity in rece...
We investigated the impact of neutralizing antibodies (NAbs) on CD4 T-cell count and viral load in a...
Although antiretroviral therapy (ART) successfully suppresses HIV-1 replication, ART-treated individ...
Next to a profound T cell immunodeficiency, HIV-1 infection induces activation and dysfunction of B ...
Aim. To estimate the antibodies (Ab) level to HIV-1 antigens in persons infected with virus various ...
Objectives: To evaluate the evolution of antibody avidity and Western blot reactivity in recently i...
BackgroundIn the placebo-controlled trial ACTG A5197, a trend favoring viral suppression was seen in...
Viral suppression and viral breakthrough impact the humoral immune response to HIV infection. We eva...
Viral suppression and viral breakthrough impact the humoral immune response to HIV infection. We eva...
Background: A major challenge to HIV eradication strategies is the lack of an accurate measurement o...
BACKGROUND: A major challenge to HIV eradication strategies is the lack of an accurate measurement o...
Although antiretroviral therapy (ART) suppresses HIV replication, ART-treated individuals must maint...
SummaryObjectivesTo evaluate the evolution of antibody avidity and Western blot reactivity in recent...
Objective: Persistence of the viral reservoir is the main barrier to curing HIV. Initiation of ART d...
BackgroundA major challenge to HIV eradication strategies is the lack of an accurate measurement of ...
Summary Objectives To evaluate the evolution of antibody avidity and Western blot reactivity in rece...
We investigated the impact of neutralizing antibodies (NAbs) on CD4 T-cell count and viral load in a...
Although antiretroviral therapy (ART) successfully suppresses HIV-1 replication, ART-treated individ...
Next to a profound T cell immunodeficiency, HIV-1 infection induces activation and dysfunction of B ...
Aim. To estimate the antibodies (Ab) level to HIV-1 antigens in persons infected with virus various ...
Objectives: To evaluate the evolution of antibody avidity and Western blot reactivity in recently i...
BackgroundIn the placebo-controlled trial ACTG A5197, a trend favoring viral suppression was seen in...